| Objective:Fufang Xueshuantong Capsule(cFXST),as a Chinese Traditional Medicine,has been empirically used in ophthalmology for the treatment of diabetic retinopathy,and macular edema secondary to retinal diseases.Age related macular degeneration,characterized by choroidal neovascularization,is the main retinal diseases.The exudation,bleeding of the neovascularization,or the delayed absorption of subretinal fluid or hemorrhage,disturbs the macular anatomy,and impairs the visual acuity of AMD patients.To date,there is no report on the clinic research on the cFXST in the treatment of wet AMD.This study is to determine the complementary therapeutic effect of cFXST to intravitreal injection of ranibizumab(IVR)in the treatment of wet-AMD.Methods:A total of 38 patients with wet age-related macular degeneration were included and randomly included in the Lucentis group(19 cases)and the cFXST group(19 cases)at a ratio of 1:1.Patients in Lucentis group received three monthly IVR while patients in cFXST also received daily oral supplementation of cFXST in addition to IVR.Best corrected visual acuity(BCVA)and total centerpoint thickness CNV-pigment epithelial detachment(CNV-PED)complex by optical coherence tomography(OCT)were recorded at baseline and 1 month,and 3 months after first intravitreal injection of Lucentis.Results:Nineteen patients with wet-AMD were allocated in cFXST group and 19 in Lucentis group.In cFXST group,the thickness of CNV-PED reduced by 31.7%and 36.1%at Month 1 and Month 3,respectively,higher than 19.7%(P=0.021),24.2%(P=0.018)in Lucentis group.The BCVA increase of cFXST group after 3 months was significantly higher than that of Lucentis group(P=0.045)and the proportion of patients with functional response was also higher in cFXST group after 3 months(16/16 vs 8/17,P=0.001).Conclusions:Adjunctive daily oral cFXST might be capable to increase the short-time effectiveness of anti-VEGF therapy. |
PDF Full Text Request